AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemothe

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Related Keywords

Neoadjuvant Durvalumab , John Heymach , , Adjuvant Durvalumab , Partnership With , Nsclc , Non Small Cell Lung Cancer , Early Stage Lung Cancer , Early Stage Nsclc , Durvalumab , Durvalumab Therapy , Overall Survival , Progression Free Survival , Event Free Survival , Pathologic Complete Response , Pd L1 Expression , Pd L1 Level , Adverse Events , Drug Adverse Event , Aegean Study , Aegean Trial , Efs Bicr , Dfs Bicr , Pcr , Mpr ,